89 related articles for article (PubMed ID: 24567264)
1. Purification, characterization and plasma half-life of PEGylated soluble recombinant non-HA-binding CD44.
Pink A; Kallastu A; Turkina M; Skolnaja M; Kogerman P; Päll T; Valkna A
BioDrugs; 2014 Aug; 28(4):393-402. PubMed ID: 24567264
[TBL] [Abstract][Full Text] [Related]
2. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid.
Ahrens T; Sleeman JP; Schempp CM; Howells N; Hofmann M; Ponta H; Herrlich P; Simon JC
Oncogene; 2001 Jun; 20(26):3399-408. PubMed ID: 11423990
[TBL] [Abstract][Full Text] [Related]
4. Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding.
Päll T; Gad A; Kasak L; Drews M; Strömblad S; Kogerman P
Oncogene; 2004 Oct; 23(47):7874-81. PubMed ID: 15361838
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD44 interacts with intermediate filament protein vimentin on endothelial cell surface.
Päll T; Pink A; Kasak L; Turkina M; Anderson W; Valkna A; Kogerman P
PLoS One; 2011; 6(12):e29305. PubMed ID: 22216242
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a functional hyaluronan-binding domain from the human CD44 molecule expressed in Escherichia coli.
Banerji S; Day AJ; Kahmann JD; Jackson DG
Protein Expr Purif; 1998 Dec; 14(3):371-81. PubMed ID: 9882571
[TBL] [Abstract][Full Text] [Related]
7. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
[TBL] [Abstract][Full Text] [Related]
8. CD44v10 interaction with Rho-kinase (ROK) activates inositol 1,4,5-triphosphate (IP3) receptor-mediated Ca2+ signaling during hyaluronan (HA)-induced endothelial cell migration.
Singleton PA; Bourguignon LY
Cell Motil Cytoskeleton; 2002 Dec; 53(4):293-316. PubMed ID: 12378540
[TBL] [Abstract][Full Text] [Related]
9. Site-specific de-N-glycosylation of CD44 can activate hyaluronan binding, and CD44 activation states show distinct threshold densities for hyaluronan binding.
English NM; Lesley JF; Hyman R
Cancer Res; 1998 Aug; 58(16):3736-42. PubMed ID: 9721887
[TBL] [Abstract][Full Text] [Related]
10. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
Choi KY; Min KH; Yoon HY; Kim K; Park JH; Kwon IC; Choi K; Jeong SY
Biomaterials; 2011 Mar; 32(7):1880-9. PubMed ID: 21159377
[TBL] [Abstract][Full Text] [Related]
11. Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist.
Niv-Spector L; Shpilman M; Boisclair Y; Gertler A
Protein Expr Purif; 2012 Feb; 81(2):186-92. PubMed ID: 22040607
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the release and function of tumor cell-derived soluble CD44.
Cichy J; Kulig P; Puré E
Biochim Biophys Acta; 2005 Aug; 1745(1):59-64. PubMed ID: 16085055
[TBL] [Abstract][Full Text] [Related]
13. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis.
Mikecz K; Dennis K; Shi M; Kim JH
Arthritis Rheum; 1999 Apr; 42(4):659-68. PubMed ID: 10211879
[TBL] [Abstract][Full Text] [Related]
14. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.
Alvarez HM; So OY; Hsieh S; Shinsky-Bjorde N; Ma H; Song Y; Pang Y; Marian M; Escandón E
Drug Metab Dispos; 2012 Feb; 40(2):360-73. PubMed ID: 22083830
[TBL] [Abstract][Full Text] [Related]
15. Cytokine induction of the ability of human monocyte CD44 to bind hyaluronan is mediated primarily by TNF-alpha and is inhibited by IL-4 and IL-13.
Levesque MC; Haynes BF
J Immunol; 1997 Dec; 159(12):6184-94. PubMed ID: 9550421
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles.
Mizrahy S; Goldsmith M; Leviatan-Ben-Arye S; Kisin-Finfer E; Redy O; Srinivasan S; Shabat D; Godin B; Peer D
Nanoscale; 2014 Apr; 6(7):3742-52. PubMed ID: 24569711
[TBL] [Abstract][Full Text] [Related]
17. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding.
Liao HX; Lee DM; Levesque MC; Haynes BF
J Immunol; 1995 Oct; 155(8):3938-45. PubMed ID: 7561101
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel recombinant hyaluronan binding protein for tissue hyaluronan detection.
Jadin L; Huang L; Wei G; Zhao Q; Gelb AB; Frost GI; Jiang P; Shepard HM
J Histochem Cytochem; 2014 Sep; 62(9):672-83. PubMed ID: 24891594
[TBL] [Abstract][Full Text] [Related]
19. Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody.
Lesley J; Kincade PW; Hyman R
Eur J Immunol; 1993 Aug; 23(8):1902-9. PubMed ID: 7688309
[TBL] [Abstract][Full Text] [Related]
20. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
